KRKseniya Antonovna Rossolovskaya

Kseniya Antonovna Rossolovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kseniya Antonovna Rossolovskaya has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bovhyaluronidase azoximer in combination therapy for recurrent bacterial vaginosis: results of an open-label randomized controlled trial

    by Leonid G. Spivak, Спивак Леонид Григорьевич, Ksenia A. Rossolovskaya, Россоловская Ксения Антоновна, Igor I. Baranov, Баранов Игорь Иванович, Inna A. Apolikhina, Аполихина Инна Анатольевна, Gyuldana R. Bayramova, Байрамова Гюльдана Рауфовна, et al.

    Background. Recurrence of bacterial vaginosis (BV) after antibacterial therapy may be associated with the persistence of polymicrobial biofilms. Aim. To compare the efficacy and safety of metronidazole combined with bovhyaluronidase azoximer versus metronidazole monotherapy in recurrent BV. Materials and methods. In this open-label randomized two-center phase IV study, 100 women aged 18–45 years were randomized 1:1 to receive metronidazole monotherapy (500 mg twice daily for 7 days) or the same metronidazole regimen combined with bovhyaluronidase azoximer (3,000 IU intravaginally every other day for 10 administrations). Treatment efficacy at day 21 was assessed in 95 participants, while recurrence over 6 months was evaluated in 57 participants who achieved remission. Amsel criteria were used to diagnose BV and assess remission and recurrence. Light microscopy was used to detect clue cells and characterize the vaginal flora; culture and real-time polymerase chain reaction were used to assess cultivable microorganisms and quantitatively characterize the vaginal microbiota, respectively. Polymicrobial biofilms were visualized using transmission electron microscopy. Results. At day 21, a successful treatment outcome was achieved in 41/47 (87.2%) participants receiving combination therapy and 25/48 (52.1%) receiving monotherapy (p0.001). Combination therapy was associated with more frequent detection of rod-shaped flora in vaginal discharge (66.0% vs 43.8%; p=0.040), a higher relative abundance of Lactobacillus spp. (p=0.004), and a lower proportion of obligate anaerobes according to polymerase chain reaction (p=0.007). Culture detected Lactobacillus spp. in 80.9% versus 66.7% and Gardnerella vaginalis in 6.4% versus 18.8% of participants, respectively. Biofilms persisted in 4/47 (8.5%) and 25/48 (52.1%) participants, respectively (p0.001). At 6 months, recurrence occurred in 4/35 (11.4%) and 9/22 (40.9%) women (p=0.021), the Cox model hazard ratio for combination therapy versus monotherapy was 0.23 (95% confidence interval 0.07–0.76). Adverse events were reported in 7/100 participants. Conclusion. Adding bovhyaluronidase azoximer to metronidazole increased the remission rate, promoted restoration of the lactobacillus-dominated microbiota, reduced biofilm persistence and BV recurrence, and was associated with a favorable safety profile.

  • Open Access

    Is there an association between vaginal, urethral and urinary microbiota in women with urogenital tract diseases?

    by M. Boldyreva, A. Ivanova, M. Petrunicheva, A. Morozov, Z. Moskvina, K. Rossolovskaya, L. Spivak, М. Болдырева, А. Иванова, М. Петруничева, et al.

    Urinary tract infections (UTI), including recurrent cystitis, are usually interpreted in relation to dominant uropathogens. However, the microbial context of adjacent urogenital sites may also be relevant. Aim. To evaluate the association between UTI and the microbiota of different parts of the urogenital tract in order to provide insights into disease pathogenesis and treatment. Material and methods. The study included three groups: healthy volunteer group (n= 34); patients at risk of developing UTI (women with micronephrolithiasis and/or bacterial vaginosis; n = 16); and patients with a history of recurrent lower UTI (n = 100). Four types of biomaterial were used: first-pass and midstream urine samples, urethral and vaginal swabs. All samples were analyzed by multiplex real-time polymerase chain reaction reagent kits Femoflor®16 and BacScreen OM. Results. Genomic DNA and total bacterial quantities increased while relative lactobacilli decreased in patients with a risk of UTI and in those with recurrent lower UTI. This was only the case in midstream and first-pass urine samples. Relative lactobacilli levels in the urethral and vaginal swabs were only slightly but statistically significantly reduced in patients with recurrent lower UTI. Facultative anaerobes predominated in urine samples of patients with a risk of UTI, while in patients with recurrent lower UTI an increase in both facultative and obligate anaerobes was observed. Conclusion. Midstream and first-pass urine samples can reliably assess inflammation in the urogenital tract. No strict correlation was observed between the vaginal and urinary microbiota of patients with recurrent lower UTI, meaning that UTI do not necessarily affect the vaginal biotope.

  • Efficacy and safety of enzymatic hydrolysis in the complex treatment of bacterial vaginosis: preliminary results of a clinical trial

    by K.A. Rossolovskaya, N.S. Trifonova, A.I. Ishchenko, I.V. Gadaeva, E.E. Bragina, M.N. Boldyreva, Z.V. Moskvina, L.G. Spivak

    Bacterial vaginosis is a biofilm-related disease. Biofilms increase the resistance of microorganisms to antibiotics, which reduces the efficacy of treatment and contributes to recurrences. Clinical guidelines do not provide options to combat biofilms in the treatment of patients with bacterial vaginosis. Objective. To study the efficacy and safety of enzymatic hydrolysis of the biofilm matrix by bovhyaluronidase azoximer (BA) in bacterial vaginosis. Patients and methods. A comparative analysis of clinical and laboratory characteristics of female patients aged 18 to 45 years with bacterial vaginosis treated with metronidazole monotherapy (control group, n = 35) and a combination of metronidazole and bovhyaluronidase azoximer (BA) (study group, n = 37) was performed. To visualize and evaluate the structure of biofilms, all patients underwent electron microscopic examination of a sample from the posterior vaginal vault epithelium. Results. After treatment, the score according to Amsel’s criteria normalized in 97.3% of patients in the study group and in 54.3% of patients in the control group. Complaints of discharge (2.7% and 20%) and vaginal odor (2.7% and 25.7%), Gardnerella vaginalis growth (5.4% and 22.9%), detection of key cells (2.7% and 5.9%) and coccobacillary flora (2.7% and 23.5%) were significantly less frequent in the study group. According to the results of the Femoflor-16 test, patients in the study group had significantly more lactobacilli and fewer anaerobes. According to electron microscopy, biofilms were initially detected in 95.5% of patients in the study group and in 84.2% of patients in the control group. During treatment, their number did not change in 15 of 19 women in the control group (78.9%). In all patients in the study group (100%, n = 22), they were absent or there was a change in their structure. Conclusion. Electron microscopy in the study of a sample from the posterior vaginal vault epithelium in women with bacterial vaginosis allows us to determine the presence of biofilms and assess their structure. Combination therapy with bovhyaluronidase azoximer destroys the biofilm matrix and promotes the transition of bacteria to the planktonic form, which is accompanied by vaginal microbiome normalization, reduction in the severity of complaints and improvement in laboratory test results. Key words: bacterial biofilms, bacterial vaginosis, bovhyaluronidase azoximer, Longidaza


  • Open Access

    Bacterial vaginosis biofilms: a target for therapeutic innovation

    by Kseniya Antonovna Rossolovskaya, Natalia Syaitovna Trifonova, Irina Victorovna Gadaeva, Leonid Grigorievich Spivak

    Bacterial vaginosis (BV) is one of the most common vaginal microbiome abnormalities worldwide and a risk factor for various obstetric and gynecological complications. Despite years of exploration, existing and quickly emerging clinical, laboratory and instrumental diagnostic methods, and progressive development of science in general, the etiology and pathogenesis of BV remain poorly understood. This is evidenced by the high incidence of chronic and/or recurrent course. There are standard therapeutic approaches aimed to eradicating the causative agent, but the level of efficacy remains questionable due to recurrent episodes. Therefore, further studies of this problem are warranted. Actually, it is evident that G. vaginalis forms polymicrobial biofilms on urogenital tract mucosa. Biofilms represent associations of microorganisms that are adhered to the surface of the epithelium and connected together in the polymer matrix. Biofilms change the properties of the microorganisms involved into their structural frame and provide beneficial conditions for their interactions. This results in the increase of the existing pathogenic properties of bacteria associated with BV, as well as in the appearance of new features. Thus, the microorganisms become less susceptible to previously effective antibiotics and to aggressive media. Finally, this contributes to the recurrent course of the disease. In most cases, treatment of BV is based on the immediate effect on the microorganisms, but in patients with confirmed biofilm-associated BV this strategy is not effective and is associated with BV recurrences. Thus, currently relevant issues include exploration of the causes of recurrent BV, development of anti-biofilm agents able to disrupt their matrix and release bacteria from their carcass, and introduction of these agents into clinical practice. This will increase the effectiveness of treatment.


  • Open Access

    Simultaneous tumors: ovarian cancer in a patient with multiple myeloma

    by Igor Yu. Gadaev, Irina V. Gadaeva, Kseniya A. Rossolovskaya, Olga V. Bochkarnikova, Irina Yakovlevna Sokolova, Россоловская Ксения Антоновна

    Multiple myeloma is the second most common hematological malignancy, accounting for approximately 1% and 10–15% of malignant tumors of the hematopoietic and lymphoid systems, respectively. Until recently, the diagnosis of multiple myeloma was inherently associated with unfavorable prognosis of overall survival. On the one hand, advanced diagnosis techniques and the development of new treatment approaches have led to the improved life expectancy and significant reduction of mortality of patients with multiple myeloma. On the other hand, the medical and research communities have encountered a previously unknown issue: the combination of multiple myeloma with other types of cancer. This combination sets a task of multidisciplinary approach in the diagnosis and requires development of patient management strategy and prognostic parameters of the outcome. Some researchers adhere to the theory of independent tumor appearance in patients suffering from multiple myeloma, while other authors suppose that multiple myeloma and secondary cancer virtually represent multiple primary malignant neoplasms. This article presents a clinical case of postmortem verification of ovarian cancer in a patient with recurrent multiple myeloma.

  • Open Access

    Placebo-controlled clinical trial of the effectiveness of D-Mannose Supercomplex in the prevention of recurrent UTI.

    by Z.V. Moskvina, Russia Moscow, M.N. Boldyreva, K.A. Rossolovskaya, M.S. Evdokimov, Russia Family Polyclinic No. 4; Korolev, D.V. Platonova, Ts.G. Magomedov, L.G. Spivak

    Introduction. In recent years, the use of D-mannose as an alternative to antimicrobial agents has been widely discussed in the literature due to the fact that when applied topically, it reduces the ability of E. coli to bind to the urothelium. The aim of this study was to evaluate the change in the number of relapses during the observation period in patients who used «D-Mannose Supercomplex» as a metaphylaxis of cystitis in comparison with the control group, which received a placebo instead of this product. Materials and methods. A multicenter, randomized, double-blind, placebo-controlled, prospective clinical study was conducted to evaluate the efficacy and safety of a dietary supplement containing 2000 mg of D-mannose, 100 mg of cranberry extract, 80 mg of bearberry extract (8 mg of arbutin), and 30 mg of magnesium. Results. In animal models, the use of D-mannose led to a significant decrease in the bacterial load. The use of «D-Mannose Supercomplex» prolongs the relapse-free period in patients with RUTI after the end of antibacterial therapy. The duration of the relapse-free period correlates with the duration of D-mannose intake, which is consistent with modern concepts of the mechanism of action of the drug. The drug is well tolerated by patients. The number of adverse events (AE) in the «D-Mannose Supercomplex» and placebo groups was comparable. AE and allergic reactions associated, according to the researchers, with the use of the study drug, were not registered during the administration of the drug. Conclusions. The presented study data indicate that complex drugs containing D-mannose, cranberry extract, bearberry and magnesium (for example, «D-Mannose Supercomplex») can be considered from the standpoint of evidence-based medicine as a promising means of complex etiopathogenetic therapy for prolonging the relapse-free period in patients with exacerbation of recurrent urinary tract infection (RUTI).

  • HELLP syndrome as an interdisciplinary problem. Clinical observation

    by Irina V. Gadaeva, Igor’ Yu. Gadaev, Anna D. Koryagina, Kseniya A. Rossolovskaya, Россоловская Ксения Антоновна

    Thrombotic microangiopathy (TMA) is an important component in obstetric practice. Despite this, patients with suspected TMA should be under the supervision of not only an obstetrician-gynecologist, but also related specialists such as a hematologist, nephrologist, cardiologist, therapist, etc. The main types of TMA found in pregnant women are thrombotic thrombocytopenic purpura (TTP), catastrophic antiphospholipid syndrome (KAFS), atypical hemolytic-uremic syndrome (aHUS), preeclampsia (PE) and HELLP syndrome. The most common TMA, according to world literature, is HELLP syndrome, which, in turn, in 10-20% of cases is a complication of severe preeclampsia. In this article, we reviewed the clinical observation of the development of HELLP syndrome in a 32-year-old woman with a severe form of preeclampsia. The features of the differential diagnosis in the framework of thrombotic microangiopathy with predominant kidney damage were demonstrated. We have analyzed the issues of the origin of HELLP syndrome and the methods of treatment. This article discusses modern approaches to the diagnosis of a group of thrombotic microangiopathies found in obstetric practice. An interdisciplinary approach involving specialists such as a hematologist, a nephrologist, a clinical pharmacologist, a cardiologist, a therapist and a hemotransfusiologist is extremely important for the differential diagnosis of HELLP syndrome in a patient with severe preeclampsia, which allows you to get a positive result from timely and well-chosen therapy. The end result is a reduction in both maternal and perinatal mortality.

  • Open Access

    The role of D-mannose and proanthocyanidins in cranberries in the prevention of recurrent urinary tract infections.

    by Moskvina Z.V., Boldyreva M.N., Rossolovskaya K.A., Spivak L.G.

    Introduction. Prevention of urinary tract infections (UTI) is an urgent problem due to their high prevalence. Regular use of antibiotics, especially when recurrent urinary tract infections occur, cont